PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nirmatrelvir→

Nirmatrelvir PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2628280-40-8
Molecular formula
C23H32F3N5O4
Molecular weight
499.5 g/mol
Drug class
SARS-CoV-2 main protease (3CLpro/Mpro) inhibitorantiviral component of Paxlovid
Mechanism of action
Selectively inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication. It is administered with ritonavir, which inhibits CYP3A-mediated metabolism and increases nirmatrelvir exposure.
Indications / reported uses
  • In combination with ritonavir (PAXLOVID) for treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalisation or death, under the applicable product label; nirmatrelvir monotherapy is not the authorised regimen

Sources: US DailyMed — PAXLOVID (nirmatrelvir/ritonavir), label updated 2026 · US FDA — Paxlovid prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Nirmatrelvir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nirmatrelvir Permitted Daily Exposure (PDE) report (the Nirmatrelvir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nirmatrelvir Occupational Exposure Limit (OEL) report (the Nirmatrelvir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.